Compassionate Use of Stannsoporfin as an Adjuvant to Phototherapy to Reduce the Need for Exchange Transfusions

Trial Profile

Compassionate Use of Stannsoporfin as an Adjuvant to Phototherapy to Reduce the Need for Exchange Transfusions

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Stannsoporfin (Primary)
  • Indications Hyperbilirubinaemia; Neonatal jaundice
  • Focus Expanded access; Therapeutic Use
  • Sponsors InfaCare Pharmaceutical Corporation
  • Most Recent Events

    • 12 Dec 2016 Status changed from recruiting to completed.
    • 12 Dec 2016 Status changed from recruiting to completed.
    • 28 May 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top